We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Gilead’s Indian Covid-19 drug licensees to set own prices

Intellectual Property Magazine

Gilead’s Indian Covid-19 drug licensees to set own prices

US biopharmaceutical company Gilead will allow Indian-basedlicensed manufacturers to set their own prices for the potential Covid-19vaccine remdesivir, it has been reported.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?

Devices

Request a trial Find out more